Treatment of chronic essential hypertension.
D002740:Chlorothiazide / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000209:etiology; D004039:Diet, Sodium-Restricted; D006073:Gout / Q000209:etiology; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008487:Medical History Taking; D008750:Methyldopa / Q000627:therapeutic use; D010349:Patient Compliance; D010808:Physical Examination; D008517:Phytotherapy; D010946:Plants, Medicinal; D011188:Potassium / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011379:Prognosis; D011433:Propranolol / Q000627:therapeutic use; D011926:Rauwolfia / Q000627:therapeutic use; D013562:Sympathectomy; D014149:Tranquilizing Agents / Q000627:therapeutic use
D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents; D006830:Hydralazine; D008750:Methyldopa; D002740:Chlorothiazide; D011433:Propranolol; D003000:Clonidine; D011188:Potassium; D011224:Prazosin; D006145:Guanethidine